Phogat S, Svehla K, Tang M, Spadaccini A, Muller J, Mascola J, Berkower I, Wyatt R
Structural Virology Section, Vaccine Research Center, NIAID, NIH, Bethesda, MD 20892-3005, USA.
Virology. 2008 Mar 30;373(1):72-84. doi: 10.1016/j.virol.2007.11.005. Epub 2007 Dec 26.
Vaccine immunogens derived from the envelope glycoproteins of the human immunodeficiency virus type 1 (HIV-1) that elicit broad neutralizing antibodies remain an elusive goal. The highly conserved 30 amino-acid membrane proximal external region (MPER) of HIV gp41 contains the hydrophobic epitopes for two rare HIV-1 broad cross-reactive neutralizing antibodies, 2F5 and 4E10. Both these antibodies possess relatively hydrophobic HCDR3 loops and demonstrate enhanced binding to their epitopes in the context of the native gp160 precursor envelope glycoprotein by the intimate juxtaposition of a lipid membrane. The hepatitis B surface antigen (HBsAg) S1 protein forms nanoparticles that can be utilized both as an immunogenic array of the MPER and to provide the lipid environment needed for enhanced 2F5 and 4E10 binding. We show that recombinant HBsAg particles with MPER (HBsAg-MPER) appended at the C-terminus of the S1 protein are recognized by 2F5 and 4E10 with high affinity compared to positioning the MPER at the N-terminus or the extracellular loop (ECL) of S1. Addition of C-terminal hydrophobic residues derived from the HIV-1 Env transmembrane region further enhances recognition of the MPER by both 2F5 and 4E10. Delipidation of the HBsAg-MPER particles decreases 2F5 and 4E10 binding and subsequent reconstitution with synthetic lipids restores optimal binding. Inoculation of the particles into small animals raised cross-reactive antibodies that recognize both the MPER and HIV-1 gp160 envelope glycoproteins expressed on the cell surface; however, no neutralizing activity could be detected. Prime:Boost immunization of the HBsAg-MPER particles in sequence with HIV envelope glycoprotein proteoliposomes (Env-PLs) did not raise neutralizing antibodies that could be mapped to the MPER region. However, the Env-PLs did raise anti-Env antibodies that had the ability to neutralize selected HIV-1 isolates. The first generation HBsAg-MPER particles represent a unique means to present HIV-1 envelope glycoprotein neutralizing determinants to the immune system.
源自1型人类免疫缺陷病毒(HIV-1)包膜糖蛋白且能引发广泛中和抗体的疫苗免疫原仍是一个难以实现的目标。HIV gp41高度保守的30个氨基酸的膜近端外部区域(MPER)包含两种罕见的HIV-1广泛交叉反应中和抗体2F5和4E10的疏水表位。这两种抗体都具有相对疏水的重链互补决定区3(HCDR3)环,并且通过脂质膜的紧密并置,在天然gp160前体包膜糖蛋白的背景下表现出与它们的表位增强的结合。乙型肝炎表面抗原(HBsAg)S1蛋白形成纳米颗粒,既可以用作MPER的免疫原性阵列,又可以提供增强2F5和4E10结合所需的脂质环境。我们表明,与将MPER定位在S1蛋白的N端或细胞外环(ECL)相比,在S1蛋白的C端附加有MPER的重组HBsAg颗粒(HBsAg-MPER)能被2F5和4E10以高亲和力识别。添加源自HIV-1 Env跨膜区域的C端疏水残基进一步增强了2F5和4E10对MPER的识别。HBsAg-MPER颗粒的去脂作用降低了2F5和4E10的结合,随后用合成脂质重建可恢复最佳结合。将这些颗粒接种到小动物体内可产生交叉反应抗体,这些抗体可识别MPER和细胞表面表达的HIV-1 gp160包膜糖蛋白;然而,未检测到中和活性。用HIV包膜糖蛋白蛋白脂质体(Env-PLs)依次对HBsAg-MPER颗粒进行初免-加强免疫,未产生可定位到MPER区域的中和抗体。然而,Env-PLs确实产生了具有中和选定HIV-1分离株能力的抗Env抗体。第一代HBsAg-MPER颗粒代表了一种向免疫系统呈递HIV-1包膜糖蛋白中和决定簇的独特方法。